Date: Nov 5, 2023
Your Name: Yiping Luo

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	✓ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for lectures, presentations,	<u>✓</u> None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	<u>✓</u> None	
7	Support for attending meetings and/or travel	<u>√</u> None	
	,		
8	Patents planned, issued or pending	<u>✓</u> None	
	pending		
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	✓ None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<u>✓</u> None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	<u>✓</u> None	
	financial interests		

Dr. Luo has nothing to disclose.					

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov 5, 2023
Your Name: Kangni Lin

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>✓</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>✓</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	✓ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>✓</u> None	
	testimony		
	-		
7	Support for attending meetings and/or travel	<u>✓</u> None	
8	Patents planned, issued or	<u>✓</u> None	
	pending		
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>✓</u> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	(1)	
11	Stock or stock options	<u>✓</u> None	
12	Receipt of equipment,	✓ None	
12	materials, drugs, medical	<u>V</u> INUITE	
	writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
		•	

Dr. Lin has nothing to disclose.	Dr. Lin has nothing to disclose.					

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov 5, 2023

Your Name: Mingji Zhang

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	✓ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>✓</u> None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>✓</u> None	
	testimony		
7	Support for attending	Alama	
/	meetings and/or travel	<u>✓</u> None	
8	Patents planned, issued or	<u>✓</u> None	
	pending		
_			
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	✓ None	
10	in other board, society,	<u>v</u> None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>✓</u> None	
12	Descint of annique out	Alama	
12	Receipt of equipment, materials, drugs, medical	<u>✓</u> None	
	writing, gifts or other		
	services		
13	Other financial or non-	<u>✓</u> None	
	financial interests		

Dr. Zhang has nothing to disclose.				

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov 5, 2023

Your Name: Taichiro Goto

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>✓</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>✓</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>✓</u> None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	✓ None	
	testimony		
7	Support for attending meetings and/or travel	<u>✓</u> None	
8	Patents planned, issued or	<u>✓</u> None	
	pending		
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	/ NI - II -	
10	in other board, society,	<u>✓</u> None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	<u>✓</u> None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	<u>✓</u> None	
	financial interests		

Dr. Goto has nothing to disclose.					

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023/11/6

Your Name: Wolfgang Brueckl, MD

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning or	f the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	_X_None	
	No time limit for this item.		
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	X_None	
5	Payment or honoraria for lectures, presentations, speakers bureaus,	AstraZeneca Boehringer Novartis	lecture fees, educational events, personal lecture fees, educational events, personal lecture fees, personal
	manuscript writing or	MSD	lecture fees, personal

	educational events	BMS	lecture fees, personal
		Roche	lecture fees, educational events, personal
		Lilly	Lecture fees, educational events, personal
		Pfizer	Lecture fees, educational events, personal
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	Boehringer	congress fees, personal
		AstraZeneca	congress fees, personal
		Roche Pharma	Congress fees, personal
8	Patents planned, issued or		EP21183549.1
	pending		method for predicting a clinical response
			towards an immune checkpoint inhibitor
			based on pretreatment therewith
9	Participation on a Data	AstraZeneca	Adboard, personal
	Safety Monitoring Board or	Boehringer	Adboard, personal
	Advisory Board	Novartis	Adboard, personal
		MSD	Adboard, personal
		Lilly Pharma	Adboard, personal
		BMS	Adboard, personal
		Roche	Adboard, personal
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	Boehringer	medical writing
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_XNone	
	financial interests		

The author received honoraria for lectures or educational events from AstraZeneca, Boehringer, Novartis, MSD, BMS, Lilly, Pfizer and Roche. The author received support for attending meetings and/or travel from Boehringer, Roche and AstraZeneca. The author served on advisory board of Astra Zeneca, Boehringer, Novartis, MSD, Lilly Pharma, BMS, and Roche. The author received equipment, material, drugs, medical writing, gifts or other services from Boehringer for medical writing. The author's patent application EP21183549.1 (method for predicting a clinical response towards an immune checkpoint inhibitor based on pretreatment therewith) was filed with regard to the results of this study.

# Please place an "X" next to the following statement to indicate your agreement:

Date: Nov 5, 2023
Your Name: Jingping Lin

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments  (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	<u>✓</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	✓ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>✓</u> None	
	testimony		
	-		
7	Support for attending meetings and/or travel	<u>✓</u> None	
8	Patents planned, issued or	<u>✓</u> None	
	pending		
9	Participation on a Data	<u>✓</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>✓</u> None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	(1)	
11	Stock or stock options	<u>✓</u> None	
12	Receipt of equipment,	✓ None	
12	materials, drugs, medical	<u>V</u> INUITE	
	writing, gifts or other		
	services		
13	Other financial or non-	✓ None	
	financial interests		
		•	

Dr. Lin has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov 5, 2023 Your Name: Xinwei Liu

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>✓</u> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>✓</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	✓None	
6	Payment for expert testimony	<u>✓</u> None	
7	Support for attending meetings and/or travel	✓None	
8	Patents planned, issued or pending	✓None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	✓None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	✓None	
11	Stock or stock options	✓None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>✓</u> None	
13	Other financial or non- financial interests	<u>✓</u> None	

Dr. Liu has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov 5, 2023

Your Name: Jinsen Weng

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall survival

of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	✓ None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>✓</u> None	
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for	<u>✓</u> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	✓ None	
0	testimony	<u>v</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel	<u>V</u> NOTIC	
	g: 1, 1, 1		
8	Patents planned, issued or	<u>✓</u> None	
	pending		
9	Participation on a Data Safety Monitoring Board or	<u>✓</u> None	
	Advisory Board		
10	Leadership or fiduciary role	<u>✓</u> None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
	took of stock options	<u></u> 110110	
12	Receipt of equipment,	<u>✓</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services	4	
13	Other financial or non- financial interests	<u>✓</u> None	
	illiancial interests		

Dr. Weng has nothing to disclose.			

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov 5, 2023
Your Name: Yong Ye

Manuscript Title: Combination of the platelet-to-lymphocyte ratio and fibrinogen may predict 5-year overall

survival of patient in non-small cell lung cancer treated with surgery

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>✓</u> None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	✓ None	
	any entity (if not indicated	<u>v</u> .vone	
	in item #1 above).		
3	Royalties or licenses	<u>✓</u> None	
4	Consulting fees	<u>✓</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>✓</u> None	
6	Payment for expert testimony	<u>✓</u> None	
7	Support for attending	Alama	
7	meetings and/or travel	<u>✓</u> None	
8	Patents planned, issued or pending	<u>✓</u> None	
_			
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>✓</u> None	
10	· ·	✓ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>v</u> None	
11	Stock or stock options	<u>✓</u> None	
12	Descint of annique out	Alama	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>✓</u> None	
13	Other financial or non- financial interests	<u>✓</u> None	

Dr. Ye has nothing to disclose.						

Please place an "X" next to the following statement to indicate your agreement: